Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leyvraz

Showing results (391-400 of 405) with videos related to

Pageof 41
Sort By:
Blood|July 29, 2006
Maintenance therapy with thalidomide improves survival in patients with multiple myelomaMichel Attal, Jean-Luc Harousseau, Serge Leyvraz, et al.
European Journal of Cancer (Oxford, England : 1990)|March 28, 2024
A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanomaJoseph J Sacco, Richard Jackson, Pippa Corrie, et al.
The New England Journal of Medicine|May 11, 2012
Lenalidomide maintenance after stem-cell transplantation for multiple myelomaMichel Attal, Valerie Lauwers-Cances, Gerald Marit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2012
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failureGeorge D Demetri, Christopher R Garrett, Patrick Schöffski, et al.
Nature Medicine|October 13, 2022
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trialRichard D Carvajal, Marcus O Butler, Alexander N Shoushtari, et al.
Haematologica|March 15, 2015
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomideMichel Delforge, Leonard Minuk, Jean-Claude Eisenmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2017
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose LevelsPaolo G Casali, John Zalcberg, Axel Le Cesne, et al.
Cancer|September 28, 2023
Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomasShivaani Kummar, Lin Shen, David S Hong, et al.
Leukemia|July 13, 2007
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trialsP Moreau, M Attal, F Garban, et al.
Cancer Research Communications|September 15, 2023
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other TumorsGlenn J Hanna, Anastasios Stathis, Elena Lopez-Miranda, et al.
Pageof 41

Showing results (391-400 of 405) with videos related to

Sort By:
Pageof 41
Blood|July 29, 2006
Maintenance therapy with thalidomide improves survival in patients with multiple myelomaMichel Attal, Jean-Luc Harousseau, Serge Leyvraz, et al.
European Journal of Cancer (Oxford, England : 1990)|March 28, 2024
A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanomaJoseph J Sacco, Richard Jackson, Pippa Corrie, et al.
The New England Journal of Medicine|May 11, 2012
Lenalidomide maintenance after stem-cell transplantation for multiple myelomaMichel Attal, Valerie Lauwers-Cances, Gerald Marit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2012
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failureGeorge D Demetri, Christopher R Garrett, Patrick Schöffski, et al.
Nature Medicine|October 13, 2022
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trialRichard D Carvajal, Marcus O Butler, Alexander N Shoushtari, et al.
Haematologica|March 15, 2015
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomideMichel Delforge, Leonard Minuk, Jean-Claude Eisenmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2017
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose LevelsPaolo G Casali, John Zalcberg, Axel Le Cesne, et al.
Cancer|September 28, 2023
Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomasShivaani Kummar, Lin Shen, David S Hong, et al.
Leukemia|July 13, 2007
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trialsP Moreau, M Attal, F Garban, et al.
Cancer Research Communications|September 15, 2023
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other TumorsGlenn J Hanna, Anastasios Stathis, Elena Lopez-Miranda, et al.
Pageof 41